. Author manuscript; available in PMC: 2010 May 1.

Published in final edited form as: Health Aff (Millwood). 2009 May–Jun;28(3):734–745. doi: 10.1377/hlthaff.28.3.734

Exhibit 4.

Results from Kaplan-Meier Analysis of Time to Antidepressant Discontinuation

Cohort	Median Days to Discontinuation	Relative Risk [Comparison to Reformulation]	95% Confidence Interval	# of Matched Pairs
Non-contemporaneous Matched Samples
Lexapro	91	0.83	(0.80, 0.85)	18,045
Celexa	64	0.83	(0.80, 0.85)	18,045
Paxil CR	64	0.87	(0.85, 0.89)	23,713
Paxil	61	0.87	(0.85, 0.89)	23,713
Remeron Soltab	65	1.04	(1.00, 1.08)	10,820
Remeron	66	1.04	(1.00, 1.08)	10,820
Contemporaneous Matched Samples
Lexapro	76	0.84	(0.80, 0.87)	7,985
Celexa	61	0.84	(0.80, 0.87)	7,985
Paxil CR	63	0.88	(0.85, 0.91)	14,307
Paxil	61	0.88	(0.85, 0.91)	14,307
Remeron Soltab	63	0.94	(0.90, 0.98)	9,888
Remeron	61	0.94	(0.90, 0.98)	9,888

Note: Kaplan-Meier plots are presented the Appendix.